bendamustin koanaa 2,5 mg/ml pulver für ein konzentrat zur herstellung einer infusionslösung
koanaa healthcare spain - bendamustin hydrochlorid monohydrat -
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunsuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
bendamustin accord 2,5 mg/ml pulver für ein konzentrat zur herstellung einer infusionslösung
accord healthcare b.v. - bendamustin hydrochlorid monohydrat -
bortezomib onkovis 3,5 mg pulver zur herstellung einer injektionslösung
onkovis gmbh (8111905) - bortezomibanhydrid - pulver zur herstellung einer injektionslösung - teil 1 - pulver zur herstellung einer injektionslösung; bortezomibanhydrid (43230) 3,336 milligramm
bendamustin lntas 2,5 mg/ml pulver für ein konzentrat zur herstellung einer infusionslösung
intas pharmaceuticals ltd - bendamustin hydrochlorid monohydrat -
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
abormib 1 mg-pulver zur herstellung einer injektionslösung
g.l. pharma gmbh - bortezomib -
bortezomib denk 3,5 mg pulver zur herstellung einer injektionslösung
denk pharma gmbh & co. kg (8128863) - bortezomibanhydrid - pulver zur herstellung einer injektionslösung - teil 1 - pulver zur herstellung einer injektionslösung; bortezomibanhydrid (43230) 3,366 milligramm
bortezomib ever pharma 2,5 mg/ml injektionslösung
ever valinject gmbh - bortezomib -
abormib 2,5 mg-pulver zur herstellung einer injektionslösung
g.l. pharma gmbh - bortezomib -